

ASX ANNOUNCEMENT

ANAGENICS LIMITED (ASX: AN1) – PLACEMENT

SYDNEY, 7 February 2024

Completion of Placement

Anagenics Limited (ASX: AN1) (“**the Company**” or “**AN1**”) is pleased to announce the successful completion of a two-tranche placement of new fully paid ordinary shares (“**New Shares**”) to sophisticated, professional and institutional investors to raise approximately **\$1.3m** (before costs) at a fixed offer price of **\$0.016** per New Share (“**Placement**”).

The Placement received strong support from both new and existing investors, with a number of new high-quality investors set to join the share register. AN1’s major shareholder, Hancock & Gore Limited (ASX: HNG) (“**HNG**”) and directors Sandy Beard, Phillip Christopher, Scott Greasley and Karen Matthews, have also committed to participate in the Placement subject to shareholder approval (see details below).

The offer price of the Placement of \$0.016 per New Share (“**Offer Price**”):

- is equal to the last closing price of shares on Friday 2 February 2024 (before AN1 entered a trading halt on Monday 5 February 2024); and
- represents a 5.0% premium to the 5-day volume weighted average price of \$0.015.

The Board believes that the Placement will ensure the Company is well positioned to consider potential new M&A opportunities and advance the integration of Face MediGroup.

Placement Details

The Placement will comprise:

- **Tranche 1:** an unconditional placement of approximately 40.4 million New Shares (in aggregate) within the Company’s existing placement capacity (of which 37.9 million New Shares are expected to be issued within the capacity under ASX Listing Rule 7.1A and the balance within the capacity under ASX Listing Rule 7.1) to raise \$0.6 million; and
- **Tranche 2:** a conditional placement of 42.2 million New Shares to raise \$0.7 million, subject to shareholder approval at an upcoming general meeting of the Company.

AN1 is pleased to confirm that commitments to participate in Tranche 2 of the Placement were received from major shareholder HNG (as to \$0.5 million), and AN1 directors (or their nominees) including Sandy Beard, Phillip Christopher, Scott Greasley and Karen Matthews (as to \$0.1 million). The participation by HNG demonstrates its continued support for the Company and its future objectives. Further information in relation to Tranche 2 will be contained in the notice of meeting which the Company expects to dispatch to shareholders in late February 2024.

All New Shares issued under the Placement will rank equally with existing fully paid ordinary shares in the Company as at the date of this announcement.

Bell Potter is acting as lead manager, bookrunner and agent of the Company in connection with the Placement. Details regarding options issued to Bell Potter, as part of the placement are detailed in the Appendix 3B released 7 February 2024.

Further details of the Placement are contained in the capital raising presentation which will be released to the ASX in connection with this announcement.

Use of Funds

The Company intends to apply proceeds from the Placement (together with existing cash reserves) towards:

ANAGENICS

- Future M&A opportunities
- Cost-out initiatives and integration of previous acquisitions
- Working capital and costs associated with the Placement

Timetable

The indicative timetable for the Placement is:

Event	Date
Trading halt	Monday, 5 February 2024
Announce completion of Placement bookbuild, trading halt lifted and recommence trading	Wednesday, 7 February 2024
Settlement of Tranche 1	Wednesday, 14 February 2024
Issue and quotation of shares under Tranche 1	Thursday, 15 February 2024
General meeting to ratify Tranche 1 and approve issue of shares under Tranche 2	Tuesday, 2 April 2024
Settlement of Tranche 2	Wednesday, 3 April 2024
Issue and quotation of shares under Tranche 2	Thursday, 4 April 2024

All dates are indicative only and subject to change. In particular, the timing to convene the general meeting to approve Tranche 2 may be deferred by the Company. The Company reserves the right to amend any or all of these dates subject to the Corporations Act, the Listing Rules and other applicable laws, at its discretion.

Approved for release by the Board of Directors.

Scott Greasley

CEO

+61 412 308 263

info@anagenics.com

Anagenics Limited (ASX: AN1)

Anagenics is a health and beauty-tech business growing shareholder value through the global distribution and sales of its proprietary and licensed brands of differentiated, clinically validated anti-aging solutions. BLC Cosmetics Pty Ltd is Anagenics' wholly owned subsidiary focused on sales and distribution of leading Australian and international brands of cosmetic and wellness products. For further information, please see www.anagenics.com.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Anagenics to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as, amongst other, the availability of resources, regulatory environment, the results of marketing and sales activities and competition.